Skip to main content
Top
Published in: Tumor Biology 4/2014

01-04-2014 | Research Article

Prognostic significance of dickkopf-1 overexpression in solid tumors: a meta-analysis

Authors: Yanqiong Liu, Weizhong Tang, Li Xie, Jian Wang, Yan Deng, Qiliu Peng, Limin Zhai, Shan Li, Xue Qin

Published in: Tumor Biology | Issue 4/2014

Login to get access

Abstract

The prognostic significance of dickkopf-1 (DKK1) overexpression in solid tumors remains inconclusive. We performed a meta-analysis to evaluate the impact of DKK1 overexpression in solid tumors on patients' overall survival (OS) and disease-free survival (DFS). The pooled hazard ratio (HR) with 95 % confidence interval (CI) was used to estimate the effects. Thirteen studies were included for meta-analysis; four that evaluated hepatocellular carcinoma (HCC), two each that evaluated ovarian carcinoma, esophageal carcinoma, and lung cancer, and one each that evaluated other cancers, namely gastric cancer, breast cancer, urothelial carcinoma, and colorectal cancer. Twelve studies were evaluable for OS and six for DFS. Our analysis results indicated that DKK1 overexpression predicted poor OS (HR = 1.68, 95 % CI 1.36–2.08; P < 0.001) and DFS (HR = 1.65, 95 % CI 1.37–1.99; P < 0.001). Subgroup analyses showed that DKK1 overexpression was significantly related with poor OS in HCC patients (HR = 1.65; P < 0.001), ovarian carcinoma patients (HR = 2.63; P = 0.045), and other cancers patients (HR = 1.51; P = 0.021). Further, DKK1 overexpression was significantly related with poor DFS in HCC patients (HR = 1.53; P < 0.001) and other cancers patients (HR = 2.02; P < 0.001). This meta-analysis showed that DKK1 may be a novel prognostic marker in solid tumors in Asian patients; it could potentially help to further stratify patients for clinical treatment. More, well-designed studies from Western countries are needed to confirm this finding.
Appendix
Available only for authorised users
Literature
1.
go back to reference Paul D, Kumar A, Gajbhiye A, Santra MK, Srikanth R. Mass spectrometry-based proteomics in molecular diagnostics: discovery of cancer biomarkers using tissue culture. Biomed Res Int. 2013;2013:783131.PubMedCentralPubMedCrossRef Paul D, Kumar A, Gajbhiye A, Santra MK, Srikanth R. Mass spectrometry-based proteomics in molecular diagnostics: discovery of cancer biomarkers using tissue culture. Biomed Res Int. 2013;2013:783131.PubMedCentralPubMedCrossRef
2.
go back to reference Zhang CH, Xu GL, Jia WD, Ge YS, Li JS, Ma JL, et al. Prognostic significance of osteopontin in hepatocellular carcinoma: a meta-analysis. Int J Cancer J Int Du Cancer. 2012;130:2685–92.CrossRef Zhang CH, Xu GL, Jia WD, Ge YS, Li JS, Ma JL, et al. Prognostic significance of osteopontin in hepatocellular carcinoma: a meta-analysis. Int J Cancer J Int Du Cancer. 2012;130:2685–92.CrossRef
3.
go back to reference Jiang JW, Liang XH, Zhou XL, Huang RF, Chu ZH, Zhan Q. Ercc1 expression as a prognostic and predictive factor in patients with non-small cell lung cancer: a meta-analysis. Mol Biol Rep. 2012;39:6933–42.PubMedCrossRef Jiang JW, Liang XH, Zhou XL, Huang RF, Chu ZH, Zhan Q. Ercc1 expression as a prognostic and predictive factor in patients with non-small cell lung cancer: a meta-analysis. Mol Biol Rep. 2012;39:6933–42.PubMedCrossRef
4.
go back to reference Yang H, Chen B. Cd147 in ovarian and other cancers. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc. 2013;23:2–8.CrossRef Yang H, Chen B. Cd147 in ovarian and other cancers. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc. 2013;23:2–8.CrossRef
5.
go back to reference Ma X, Liu L, Nie W, Li Y, Zhang B, Zhang J, et al. Prognostic role of caveolin in breast cancer: a meta-analysis. Breast. 2013;22:462–9.PubMedCrossRef Ma X, Liu L, Nie W, Li Y, Zhang B, Zhang J, et al. Prognostic role of caveolin in breast cancer: a meta-analysis. Breast. 2013;22:462–9.PubMedCrossRef
6.
go back to reference Glinka A, Wu W, Delius H, Monaghan AP, Blumenstock C, Niehrs C. Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction. Nature. 1998;391:357–62.PubMedCrossRef Glinka A, Wu W, Delius H, Monaghan AP, Blumenstock C, Niehrs C. Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction. Nature. 1998;391:357–62.PubMedCrossRef
7.
go back to reference Niida A, Hiroko T, Kasai M, Furukawa Y, Nakamura Y, Suzuki Y, et al. Dkk1, a negative regulator of wnt signaling, is a target of the beta-catenin/tcf pathway. Oncogene. 2004;23:8520–6.PubMedCrossRef Niida A, Hiroko T, Kasai M, Furukawa Y, Nakamura Y, Suzuki Y, et al. Dkk1, a negative regulator of wnt signaling, is a target of the beta-catenin/tcf pathway. Oncogene. 2004;23:8520–6.PubMedCrossRef
8.
go back to reference Sato N, Yamabuki T, Takano A, Koinuma J, Aragaki M, Masuda K, et al. Wnt inhibitor dickkopf-1 as a target for passive cancer immunotherapy. Cancer Res. 2010;70:5326–36.PubMedCrossRef Sato N, Yamabuki T, Takano A, Koinuma J, Aragaki M, Masuda K, et al. Wnt inhibitor dickkopf-1 as a target for passive cancer immunotherapy. Cancer Res. 2010;70:5326–36.PubMedCrossRef
9.
go back to reference Forget MA, Turcotte S, Beauseigle D, Godin-Ethier J, Pelletier S, Martin J, et al. The wnt pathway regulator dkk1 is preferentially expressed in hormone-resistant breast tumours and in some common cancer types. Br J Cancer. 2007;96:646–53.PubMedCentralPubMedCrossRef Forget MA, Turcotte S, Beauseigle D, Godin-Ethier J, Pelletier S, Martin J, et al. The wnt pathway regulator dkk1 is preferentially expressed in hormone-resistant breast tumours and in some common cancer types. Br J Cancer. 2007;96:646–53.PubMedCentralPubMedCrossRef
10.
go back to reference Jiang T, Huang L, Zhang S. Dkk-1 in serum as a clinical and prognostic factor in patients with cervical cancer. Int J Biol Markers. 2013;28:e221–5.CrossRef Jiang T, Huang L, Zhang S. Dkk-1 in serum as a clinical and prognostic factor in patients with cervical cancer. Int J Biol Markers. 2013;28:e221–5.CrossRef
11.
go back to reference Gao C, Xie R, Ren C, Yang X. Dickkopf-1 expression is a novel prognostic marker for gastric cancer. J Biomed Biotechnol. 2012;2012:804592.PubMedCentralPubMed Gao C, Xie R, Ren C, Yang X. Dickkopf-1 expression is a novel prognostic marker for gastric cancer. J Biomed Biotechnol. 2012;2012:804592.PubMedCentralPubMed
12.
go back to reference Hall CL, Daignault SD, Shah RB, Pienta KJ, Keller ET. Dickkopf-1 expression increases early in prostate cancer development and decreases during progression from primary tumor to metastasis. Prostate. 2008;68:1396–404.PubMedCentralPubMedCrossRef Hall CL, Daignault SD, Shah RB, Pienta KJ, Keller ET. Dickkopf-1 expression increases early in prostate cancer development and decreases during progression from primary tumor to metastasis. Prostate. 2008;68:1396–404.PubMedCentralPubMedCrossRef
13.
go back to reference Yang H, Chen GD, Fang F, Liu Z, Lau SH, Zhang JF, Lau WY, Yang LY: Dickkopf-1: as a diagnostic and prognostic serum marker for early hepatocellular carcinoma. The International journal of biological markers 2013:0. Yang H, Chen GD, Fang F, Liu Z, Lau SH, Zhang JF, Lau WY, Yang LY: Dickkopf-1: as a diagnostic and prognostic serum marker for early hepatocellular carcinoma. The International journal of biological markers 2013:0.
14.
go back to reference Tao YM, Liu Z, Liu HL. Dickkopf-1 (dkk1) promotes invasion and metastasis of hepatocellular carcinoma. Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver. 2013;45:251–7.CrossRef Tao YM, Liu Z, Liu HL. Dickkopf-1 (dkk1) promotes invasion and metastasis of hepatocellular carcinoma. Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver. 2013;45:251–7.CrossRef
15.
go back to reference Lee HS, Lee HE, Park Do J, Kim HH, Kim WH, Park KU. Clinical significance of serum and tissue dickkopf-1 levels in patients with gastric cancer. Clinica chimica acta. Int J Clin Chem. 2012;413:1753–60. Lee HS, Lee HE, Park Do J, Kim HH, Kim WH, Park KU. Clinical significance of serum and tissue dickkopf-1 levels in patients with gastric cancer. Clinica chimica acta. Int J Clin Chem. 2012;413:1753–60.
16.
go back to reference Wang S, Zhang S. Dickkopf-1 is frequently overexpressed in ovarian serous carcinoma and involved in tumor invasion. Clin Exp Metastasis. 2011;28:581–91.PubMedCrossRef Wang S, Zhang S. Dickkopf-1 is frequently overexpressed in ovarian serous carcinoma and involved in tumor invasion. Clin Exp Metastasis. 2011;28:581–91.PubMedCrossRef
17.
go back to reference Yu B, Yang X, Xu Y, Yao G, Shu H, Lin B, et al. Elevated expression of dkk1 is associated with cytoplasmic/nuclear beta-catenin accumulation and poor prognosis in hepatocellular carcinomas. J Hepatol. 2009;50:948–57.PubMedCrossRef Yu B, Yang X, Xu Y, Yao G, Shu H, Lin B, et al. Elevated expression of dkk1 is associated with cytoplasmic/nuclear beta-catenin accumulation and poor prognosis in hepatocellular carcinomas. J Hepatol. 2009;50:948–57.PubMedCrossRef
18.
go back to reference Shizhuo W, Tao J, Shulan Z, Bing Z. The expression and significance of dickkopf-1 in epithelial ovarian carcinoma. Int J Biol Markers. 2009;24:165–70.PubMed Shizhuo W, Tao J, Shulan Z, Bing Z. The expression and significance of dickkopf-1 in epithelial ovarian carcinoma. Int J Biol Markers. 2009;24:165–70.PubMed
19.
go back to reference Sheng SL, Huang G, Yu B, Qin WX. Clinical significance and prognostic value of serum dickkopf-1 concentrations in patients with lung cancer. Clin Chem. 2009;55:1656–64.PubMedCrossRef Sheng SL, Huang G, Yu B, Qin WX. Clinical significance and prognostic value of serum dickkopf-1 concentrations in patients with lung cancer. Clin Chem. 2009;55:1656–64.PubMedCrossRef
20.
go back to reference Makino T, Yamasaki M, Takemasa I, Takeno A, Nakamura Y, Miyata H, et al. Dickkopf-1 expression as a marker for predicting clinical outcome in esophageal squamous cell carcinoma. Ann Surg Oncol. 2009;16:2058–64.PubMedCrossRef Makino T, Yamasaki M, Takemasa I, Takeno A, Nakamura Y, Miyata H, et al. Dickkopf-1 expression as a marker for predicting clinical outcome in esophageal squamous cell carcinoma. Ann Surg Oncol. 2009;16:2058–64.PubMedCrossRef
21.
go back to reference Yamabuki T, Takano A, Hayama S, Ishikawa N, Kato T, Miyamoto M, et al. Dikkopf-1 as a novel serologic and prognostic biomarker for lung and esophageal carcinomas. Cancer Res. 2007;67:2517–25.PubMedCrossRef Yamabuki T, Takano A, Hayama S, Ishikawa N, Kato T, Miyamoto M, et al. Dikkopf-1 as a novel serologic and prognostic biomarker for lung and esophageal carcinomas. Cancer Res. 2007;67:2517–25.PubMedCrossRef
22.
go back to reference Xu WH. Liu ZB, Yang C, Qin W, Shao ZM: Expression of dickkopf-1 and beta-catenin related to the prognosis of breast cancer patients with triple negative phenotype. PLoS One. 2012;7:e37624.PubMedCentralPubMedCrossRef Xu WH. Liu ZB, Yang C, Qin W, Shao ZM: Expression of dickkopf-1 and beta-catenin related to the prognosis of breast cancer patients with triple negative phenotype. PLoS One. 2012;7:e37624.PubMedCentralPubMedCrossRef
23.
go back to reference Tung EK, Mak CK, Fatima S, Lo RC, Zhao H, Zhang C, et al. Clinicopathological and prognostic significance of serum and tissue dickkopf-1 levels in human hepatocellular carcinoma. Liver Int Off J Int Assoc Study Liver. 2011;31:1494–504.CrossRef Tung EK, Mak CK, Fatima S, Lo RC, Zhao H, Zhang C, et al. Clinicopathological and prognostic significance of serum and tissue dickkopf-1 levels in human hepatocellular carcinoma. Liver Int Off J Int Assoc Study Liver. 2011;31:1494–504.CrossRef
24.
go back to reference Shen CH, Hsieh HY, Wang YH, Chen SY, Tung CL, Wu JD, et al. High dickkopf-1 expression is associated with poor prognosis in patients with advanced urothelial carcinoma. Exp Ther Med. 2010;1:893–8.PubMedCentralPubMed Shen CH, Hsieh HY, Wang YH, Chen SY, Tung CL, Wu JD, et al. High dickkopf-1 expression is associated with poor prognosis in patients with advanced urothelial carcinoma. Exp Ther Med. 2010;1:893–8.PubMedCentralPubMed
25.
go back to reference Hao JM, Chen JZ, Sui HM, Si-Ma XQ, Li GQ, Liu C, et al. A five-gene signature as a potential predictor of metastasis and survival in colorectal cancer. J Pathol. 2010;220:475–89.PubMed Hao JM, Chen JZ, Sui HM, Si-Ma XQ, Li GQ, Liu C, et al. A five-gene signature as a potential predictor of metastasis and survival in colorectal cancer. J Pathol. 2010;220:475–89.PubMed
26.
go back to reference Pozzi S, Fulciniti M, Yan H, Vallet S, Eda H, Patel K, et al. In vivo and in vitro effects of a novel anti-dkk1 neutralizing antibody in multiple myeloma. Bone. 2013;53:487–96.PubMedCrossRef Pozzi S, Fulciniti M, Yan H, Vallet S, Eda H, Patel K, et al. In vivo and in vitro effects of a novel anti-dkk1 neutralizing antibody in multiple myeloma. Bone. 2013;53:487–96.PubMedCrossRef
27.
go back to reference Fulciniti M, Tassone P, Hideshima T, Vallet S, Nanjappa P, Ettenberg SA, et al. Anti-dkk1 mab (bhq880) as a potential therapeutic agent for multiple myeloma. Blood. 2009;114:371–9.PubMedCentralPubMedCrossRef Fulciniti M, Tassone P, Hideshima T, Vallet S, Nanjappa P, Ettenberg SA, et al. Anti-dkk1 mab (bhq880) as a potential therapeutic agent for multiple myeloma. Blood. 2009;114:371–9.PubMedCentralPubMedCrossRef
28.
go back to reference Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (moose) group. JAMA: J Am Med Assoc. 2000;283:2008–12.CrossRef Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (moose) group. JAMA: J Am Med Assoc. 2000;283:2008–12.CrossRef
29.
go back to reference Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P: The newcastle-ottawa scale (nos) for assessing the quality of nonrandomized studies in meta-analyses. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P: The newcastle-ottawa scale (nos) for assessing the quality of nonrandomized studies in meta-analyses.
30.
go back to reference Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17:2815–34.PubMedCrossRef Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17:2815–34.PubMedCrossRef
31.
go back to reference Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.PubMedCrossRef Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.PubMedCrossRef
32.
go back to reference Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ (Clinical research ed). 2003;327:557–60.CrossRef Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ (Clinical research ed). 2003;327:557–60.CrossRef
33.
34.
go back to reference Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed
35.
go back to reference Galbraith RF. A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med. 1988;7:889–94.PubMedCrossRef Galbraith RF. A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med. 1988;7:889–94.PubMedCrossRef
36.
go back to reference Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101.PubMedCrossRef Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101.PubMedCrossRef
37.
go back to reference Egger M. Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical research ed). 1997;315:629–34.CrossRef Egger M. Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical research ed). 1997;315:629–34.CrossRef
38.
go back to reference Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455–63.PubMedCrossRef Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455–63.PubMedCrossRef
39.
go back to reference Tung-Ping Poon R, Fan ST, Wong J. Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg. 2000;232:10–24.PubMedCentralPubMedCrossRef Tung-Ping Poon R, Fan ST, Wong J. Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg. 2000;232:10–24.PubMedCentralPubMedCrossRef
40.
go back to reference Gonzalex-Sancho JM, Aguilera O, Garcia JM, Pendas-Franco N, Pena C, Cal S, et al. The wnt antagonist dickkopf-1 gene is a downstream target of beta-catenin/tcf and is downregulated in human colon cancer. Oncogene. 2005;24:1098–103.CrossRef Gonzalex-Sancho JM, Aguilera O, Garcia JM, Pendas-Franco N, Pena C, Cal S, et al. The wnt antagonist dickkopf-1 gene is a downstream target of beta-catenin/tcf and is downregulated in human colon cancer. Oncogene. 2005;24:1098–103.CrossRef
Metadata
Title
Prognostic significance of dickkopf-1 overexpression in solid tumors: a meta-analysis
Authors
Yanqiong Liu
Weizhong Tang
Li Xie
Jian Wang
Yan Deng
Qiliu Peng
Limin Zhai
Shan Li
Xue Qin
Publication date
01-04-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 4/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1411-x

Other articles of this Issue 4/2014

Tumor Biology 4/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine